Imunon (NASDAQ:IMNN) Given “Buy” Rating at HC Wainwright

Imunon (NASDAQ:IMNN)‘s stock had its “buy” rating reissued by equities research analysts at HC Wainwright in a report issued on Thursday,Benzinga reports. They presently have a $12.00 price target on the stock.

A number of other research firms have also recently commented on IMNN. D. Boral Capital reiterated a “buy” rating and set a $29.00 price target on shares of Imunon in a report on Thursday. EF Hutton Acquisition Co. I upgraded Imunon to a “strong-buy” rating in a research note on Monday, September 23rd.

Imunon Price Performance

IMNN stock traded up $0.00 on Thursday, reaching $0.83. 385,123 shares of the company traded hands, compared to its average volume of 896,589. The firm has a fifty day simple moving average of $0.88 and a 200-day simple moving average of $1.08. The company has a market cap of $12.05 million, a P/E ratio of -0.44 and a beta of 2.12. Imunon has a one year low of $0.48 and a one year high of $3.65.

About Imunon

Imunon, Inc, a clinical-stage biotechnology company, engages in the development of immunotherapies and vaccines to treat cancer and infectious diseases. The company’s lead clinical program IMNN-001, a DNA-based immunotherapy for the localized treatment of ovarian cancer that is in Phase II clinical development.